Valacyclovir and acyclovir pharmacokinetics in immunocompromised children

Pediatric Blood and Cancer

Volumn 51, Issue 4, 2008, Pages 504-508

  Bomgaars, Lisa ^a,c   Thompson, Patrick ^a   Berg, Stacey ^a   Serabe, Baruti ^b   Aleksic, Alek ^a   Blaney, Susan ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SANFORD RESEARCH   (United States)

^c TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

Acyclovir; Pediatrics; Pharmacokinetics; Valacyclovir

Indexed keywords

ACICLOVIR; VALACICLOVIR; DRUG DERIVATIVE; VALINE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; MALE; NAUSEA; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING; DRUG EFFECT; DRUG TOXICITY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD;

ACYCLOVIR; ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; VALINE;

EID: 50349089762     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21638     Document Type: Article

References (20)

1. Shinkai I, Ohta Y. New drugs - Reports of new drugs recently approved by the FDA. Valacyclovir. Bioorg Med Chem 1996;4:1-2.
2. Burnette TC, de Miranda P. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. Drug Metab Dispos 1994;22:60-64.
3. de Miranda P, Burnette TC. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. Drug Metab Dispos 1994;22:55-59.
4. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605.
5. Soul-Lawton J, Seaber E, On N, et al. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995;39:2759-2764.
6. Hoglund M, Ljungman P, Weiler S. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J Antimicrob Chemother 2001;47:855-861.
7. Fife KH, Barbarash RA, Rudolph T, et al. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Sex Transm Dis 1997;24:481-486.
8. Fish DN, Vidaurri VA, Deeter RG. Stability of valacyclovir hydrochloride in extemporaneously prepared oral liquids. Am J Health Syst Pharm 1999;56:1957-1960.
9. Simon MW, Fish DN, Deeter RG. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. Drugs R&D 2002;3:365-373.
10. Page T, Sherwood C, Connor JD, et al. Simple reversed-phase high-performance liquid chromatography quantitation of ganciclovir in human serum and urine. J Chromatogr 1996;675:342-346.
11. Eksborg S, Pal N, Kalin M, et al. Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: Can intravenous acyclovir be substituted by oral valacyclovir? Med Pediatr Oncol 2002;38:240-246.
12. Nadal D, Leverger G, Sokal EM, et al. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. J Infect Dis 2002;186:S123-S130.
13. Sullender WM, Arvin AM, Diaz PS, et al. Pharmacokinetics of acyclovir suspension in infants and children. Antimicrob Agents Chemother 1987;31:1722-1726.
14. Steingrimsdottir H, Gruber A, Palm C, et al. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. Antimicrob Agents Chemother 2000;44:207-209.
15. Blum MR, Liao SH, de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med 186-192.
16. Andrei G, Sienaert R, McGuigan C, et al. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. Antimicrob Agents Chemother 2005;49:1081-1086.
17. Andrei G, Snoeck R, Reymen D, et al. Comparative activity of selected antiviral compounds against clinical isolates of varicellazoster virus. Eur J Clin Microbiol Infect Dis 1995;14:318-329.
18. Biron KK, Elion GB. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother 1980;18:443-447.
19. GlaxoSmithKline, Valtrex (valacyclovir hydrochloride) caplets. Product Information. Research Triangle Park (NC); 2007.
20. Machida H. Comparison of susceptibilities of varicella-zoster virus and herpes simplex viruses to nucleoside analogs. Antimicrob Agents Chemother 1986;29:524-526.